Market by Component (Storage, Transportation, Monitoring components), Pharma Type (Branded Drugs, Generic Drugs, OTC), Therapy Area (Communicable Diseases, Oncology, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Neurological Disorders, Pain Management, Respiratory Diseases, Other Therapy Areas), Logistics Type (Non-Cold Chain Logistics, Cold Chain Logistics) and Country Outlook | Forecast 2024-2032
Based on Triton Market Research’s report, the Europe pharmaceutical logistics market is estimated to advance at a CAGR of 7.16% during the forecasting years 2024-2032.
Report scope can be customized per your requirements - Request Free Sample Report
The demand for pharmaceutical logistics in Europe has surged, primarily due to increased needs for vaccines and drugs, further driven by COVID-19 and significant investments from leading pharmaceutical companies. Market players are striving to reduce distribution costs by developing single-source distribution channels, which further fuels market expansion. Additionally, the rise in healthcare spending has increased demand for pharmaceutical logistics. Latest estimates suggest that healthcare spending in the European Union accounted for approximately 8.4% of GDP in 2023, with countries like Germany and France being among the highest spenders.
The countries evaluated in this region include:Â
Germany spearheads the regional market, attaining $7975.74 million in 2023
Germany boasts the largest healthcare sector in Europe, leading in market volume, patient numbers, medical technology manufacturing, and healthcare provision. In 2019, the country’s pharmaceutical industry sales rose by 5.7%, reaching approximately $41.4 billion.Â
The pharmaceutical logistics market is largely supported by over 500 pharmaceutical companies, with small and mid-size enterprises (SMEs) comprising around 90% of drug manufacturers.
The pharmaceutical industry has seen a notable shift towards biological drugs, with large companies increasingly focusing on complex biologics rather than traditional small-molecule drugs. This has substantially increased the demand for pharmaceutical logistics services.Â
Market Forecast for France and the United Kingdom
French pharmaceutical companies are notably export-oriented, with international sales of brand-name drugs significantly boosting their profit margins. In 2019, the nation ranked fifth in the global pharmaceutical industry, with most of its pharmaceutical exports going to other European countries. Besides, the government has embarked on initiatives like the ‘Innovation Health 2030’ plan, which includes approximately EUR 7.5 billion investment to strengthen research to launch new biomedical products.
However, the issue of counterfeit drugs has become increasingly prominent, with around a 62% rise in seized counterfeit goods in 2021. To combat this, the nation has established stringent regulatory guidelines, which are expected to boost the operations of pharmaceutical logistics companies.Â
The UK serves as a major hub for pharmaceutical production. Home to industry giants GlaxoSmithKline (GSK) and AstraZeneca, two of the world’s top 15 pharmaceutical companies, the UK plays a significant role in this field. There is a rising demand for treatments targeting age-related illnesses, which require sophisticated temperature-controlled logistics. The need for such specialized storage and transportation solutions has led to notable growth in the pharmaceutical logistics industry.
The market is broadly sectioned into pharma type, logistics type, component, and therapy area. Based on pharma type, it includes branded, generic, and OTC drugs.Â
Branded drugs, distinguished by specific trademarks and patent protections, generate substantial revenue for manufacturers but offer lower profit margins for wholesalers and pharmacies. In countries like the US and the UK, branded drugs are preferred over generics due to favorable reimbursement policies. Although these drugs are more expensive, their perceived quality and effectiveness often justify the cost. However, the introduction of generic alternatives can quickly reduce the sales of branded drugs.
The major firms in the pharmaceutical logistics market comprise DB Schenker, DSV, Deutsche Post AG, FedEx Corporation, and Kuehne + Nagel.Â
DB Schenker, based in Germany, offers a broad range of logistics and mobility solutions, including air and ocean freight, land transport, and contract logistics. The company operates in around 2,100 locations worldwide, with 430 dedicated to land, air, and ocean freight. It provides cost-effective and time-efficient services for partial, full, and general loads. In contract logistics, DB Schenker employs about 24,500 people across 750 locations globally, delivering tailored solutions for both the trade and industrial sectors. Within the healthcare logistics sector, it serves various segments, including biopharma, pharmaceuticals, animal health, and consumer health and nutrition, offering specialized and comprehensive logistics solutions.
Latest from the Company:
In April 2024, the company announced securing Good Distribution Practice (GDP) certification in more than 150 stations. This further supports it to cover 80% of the world’s healthcare flows.
KEY DELIVERABLES OF THE REPORT:
Market CAGR during the forecasting years 2024-2032
Detailed data highlighting key insights, industry components, and market strategies
Comprehensive information and estimation of the pharmaceutical logistics market revenue growth in Europe and its influence on the parent market
In-depth study of forthcoming trends in consumer behavioral patterns
A meticulous analysis of the competitive landscape and Porter’s Five Forces
A wide-ranging study of factors that will challenge the Europe pharmaceutical logistics market’s growth during the upcoming years
Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
PHARMACEUTICAL LOGISTICS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
ANALYSIS ON THE PHARMACEUTICAL LOGISTICS MARKET
2.1.1. IMPACT
OF COVID-19
2.2. PORTER’S
FIVE FORCES ANALYSIS
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTES
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. COMPETITIVE
RIVALRY
2.3. KEY
BUYING IMPACT ANALYSIS
2.3.1. LOGISTICS
TYPE
2.3.2. SERVICES
OFFERED
2.3.3. MODE
OF TRANSPORTATION
2.3.4. APPLICATION
2.3.5. REGULATORY
COMPLIANCE
2.3.6. TECHNOLOGICAL
CAPABILITIES
2.3.7. COST
2.3.8. RELIABILITY
2.3.9. AGILITY
2.4. VALUE
CHAIN ANALYSIS
2.4.1. MANUFACTURING
2.4.2. STORAGE
2.4.3. TRANSPORTATION
2.4.4. DISTRIBUTION
2.4.5. MONITORING
COMPONENTS
2.4.6. CONSUMPTION
2.5. REGULATORY
OUTLOOK
2.6. MARKET
ATTRACTIVENESS INDEX
2.7. KEY
MARKET STRATEGIES
2.7.1. CONTRACTS
& PARTNERSHIPS
2.7.2. BUSINESS
EXPANSIONS & DIVESTITURES
2.7.3. ACQUISITIONS
& MERGERS
2.7.4. PRODUCT
LAUNCHES & DEVELOPMENTS
2.8. MARKET
DRIVERS
2.8.1. ESCALATING
DEMAND FOR TEMPERATURE-REGULATED SOLUTIONS
2.8.2. EXPANDING
OCEAN FREIGHT SERVICES
2.8.3. INCREASING
CONSUMER INCLINATION TOWARDS OVER-THE-COUNTER MEDICATIONS
2.9. MARKET
CHALLENGES
2.9.1. NECESSITY
FOR REAL-TIME TRANSPARENCY AND DEPENDABILITY
2.9.2. STRINGENT
REGULATORY MANDATES
2.10. MARKET
OPPORTUNITIES
2.10.1. RISING
OPPORTUNITIES IN CELL & GENE THERAPY LOGISTICS DUE TO INCREASED DEMAND
2.10.2. DIGITAL
TRANSFORMATION PAVING THE WAY FOR ADVANCEMENTS IN PHARMACEUTICAL LOGISTICS
2.10.3. GROWING
DEMAND FOR CLINICAL TRIAL LOGISTICS
2.11. ANALYST
PERSPECTIVE
3. EUROPE
PHARMACEUTICAL LOGISTICS MARKET - BY COMPONENT
3.1. STORAGE
3.2. TRANSPORTATION
3.3. MONITORING
COMPONENTS
4. EUROPE
PHARMACEUTICAL LOGISTICS MARKET - BY PHARMA TYPE
4.1. BRANDED
DRUGS
4.2. GENERIC
DRUGS
4.3. OTC
5. EUROPE
PHARMACEUTICAL LOGISTICS MARKET - BY LOGISTICS TYPE
5.1. NON-COLD
CHAIN LOGISTICS
5.2. COLD
CHAIN LOGISTICS
6. EUROPE
PHARMACEUTICAL LOGISTICS MARKET - BY THERAPY AREA
6.1. COMMUNICABLE
DISEASES
6.2. ONCOLOGY
6.3. DIABETES
6.4. CARDIOVASCULAR
DISEASES
6.5. AUTOIMMUNE
DISEASES
6.6. NEUROLOGICAL
DISORDERS
6.7. PAIN
MANAGEMENT
6.8. RESPIRATORY
DISEASES
6.9. OTHER
THERAPY AREAS
7. EUROPE
PHARMACEUTICAL LOGISTICS MARKET – BY COUNTRY OUTLOOK
7.1. GERMANY
7.1.1. GERMANY
PHARMACEUTICAL LOGISTICS MARKET FORECAST & PROSPECTS
7.2. UNITED
KINGDOM
7.2.1. UNITED
KINGDOM PHARMACEUTICAL LOGISTICS MARKET FORECAST & PROSPECTS
7.3. FRANCE
7.3.1. FRANCE
PHARMACEUTICAL LOGISTICS MARKET FORECAST & PROSPECTS
7.4. ITALY
7.4.1. ITALY PHARMACEUTICAL
LOGISTICS MARKET FORECAST & PROSPECTS
7.5. SPAIN
7.5.1. SPAIN
PHARMACEUTICAL LOGISTICS MARKET FORECAST & PROSPECTS
7.6. THE NETHERLANDS
7.6.1. THE NETHERLANDS
PHARMACEUTICAL LOGISTICS MARKET FORECAST & PROSPECTS
7.7. REST
OF EUROPE
7.7.1. REST
OF EUROPE PHARMACEUTICAL LOGISTICS MARKET FORECAST & PROSPECTS
8. COMPETITIVE
LANDSCAPE
8.1. AGILITY
LOGISTICS
8.1.1. OVERVIEW
8.1.2. PORTFOLIO
8.1.3. KEY
STRENGTHS
8.1.4. KEY
CHALLENGES
8.2. AP
MOLLER – MAERSK
8.2.1. OVERVIEW
8.2.2. PORTFOLIO
8.2.3. KEY
STRENGTHS
8.2.4. KEY
CHALLENGES
8.3. CARDINAL
HEALTH INC
8.3.1. OVERVIEW
8.3.2. PORTFOLIO
8.3.3. KEY
STRENGTHS
8.3.4. KEY
CHALLENGES
8.4. CENCORA
(AMERISOURCEBERGEN)
8.4.1. OVERVIEW
8.4.2. PORTFOLIO
8.4.3. KEY
STRENGTHS
8.4.4. KEY
CHALLENGES
8.5. CEVA
LOGISTICS
8.5.1. OVERVIEW
8.5.2. PORTFOLIO
8.5.3. KEY
STRENGTHS
8.5.4. KEY
CHALLENGES
8.6. DB
SCHENKER
8.6.1. OVERVIEW
8.6.2. PORTFOLIO
8.6.3. KEY
STRENGTHS
8.6.4. KEY
CHALLENGES
8.7. DEUTSCHE
POST AG
8.7.1. OVERVIEW
8.7.2. PRODUCT
PORTFOLIO
8.7.3. KEY
STRENGTHS
8.7.4. KEY
CHALLENGES
8.8. DSV
8.8.1. OVERVIEW
8.8.2. PORTFOLIO
8.8.3. KEY
STRENGTHS
8.8.4. KEY
CHALLENGES
8.9. FEDEX
CORPORATION
8.9.1. OVERVIEW
8.9.2. PORTFOLIO
8.9.3. KEY
STRENGTHS
8.9.4. KEY
CHALLENGES
8.10. KUEHNE
+ NAGEL
8.10.1. OVERVIEW
8.10.2. PORTFOLIO
8.10.3. KEY
STRENGTHS
8.10.4. KEY CHALLENGES
8.11. MARKEN
(ACQUIRED BY UPS)
8.11.1. OVERVIEW
8.11.2. PORTFOLIO
8.11.3. KEY
STRENGTHS
8.11.4. 8KEY
CHALLENGES
8.12. MEDLINE
INDUSTRIES LP
8.12.1. OVERVIEW
8.12.2. PORTFOLIO
8.12.3. KEY
STRENGTHS
8.12.4. KEY
CHALLENGES
8.13. SEKO
LOGISTICS
8.13.1. OVERVIEW
8.13.2. PORTFOLIO
8.13.3. KEY
STRENGTHS
8.13.4. KEY
CHALLENGES
8.14. UNITED
PARCEL SERVICE (UPS)
8.14.1. OVERVIEW
8.14.2. PORTFOLIO
8.14.3. KEY
STRENGTHS
8.14.4. KEY
CHALLENGES
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
TABLE 1: EUROPE PHARMACEUTICAL
LOGISTICS MARKET, BY COUNTRY OUTLOOK, HISTORICAL YEARS, 2020-2023 (IN $
MILLION)
TABLE 2: EUROPE PHARMACEUTICAL
LOGISTICS MARKET, BY COUNTRY OUTLOOK, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 3: LIST OF CONTRACTS &
PARTNERSHIPS
TABLE 4: LIST OF BUSINESS
EXPANSIONS & DIVESTITURES
TABLE 5: LIST OF ACQUISITIONS
& MERGERS
TABLE 6: LIST OF NEW PRODUCT
LAUNCHES & DEVELOPMENTS
TABLE 7: EUROPE PHARMACEUTICAL
LOGISTICS MARKET, BY COMPONENT, 2024-2032 (IN $ MILLION)
TABLE 8: EUROPE PHARMACEUTICAL
LOGISTICS MARKET, BY PHARMA TYPE, 2024-2032 (IN $ MILLION)
TABLE 9: EUROPE PHARMACEUTICAL
LOGISTICS MARKET, BY LOGISTICS TYPE, 2024-2032 (IN $ MILLION)
TABLE 10: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY THERAPY AREA, 2024-2032 (IN $ MILLION)
TABLE 11: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCES
ANALYSIS
FIGURE 2: KEY BUYING IMPACT
ANALYSIS
FIGURE 3: VALUE CHAIN ANALYSIS
FIGURE 4: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY COMPONENT, 2023 & 2032 (IN %)
FIGURE 5: EUROPE PHARMACEUTICAL
LOGISTICS MARKET, BY STORAGE, 2024-2032 (IN $ MILLION)
FIGURE 6: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY TRANSPORTATION, 2024-2032 (IN $ MILLION)
FIGURE 7: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY MONITORING COMPONENTS, 2024-2032 (IN $
MILLION)
FIGURE 8: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY PHARMA TYPE, 2023 & 2032 (IN %)
FIGURE 9: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY BRANDED DRUGS, 2024-2032 (IN $ MILLION)
FIGURE 10: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY GENERIC DRUGS, 2024-2032 (IN $ MILLION)
FIGURE 11: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY OTC, 2024-2032 (IN $ MILLION)
FIGURE 12: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY LOGISTICS TYPE, 2023 & 2032 (IN %)
FIGURE 13: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY NON-COLD CHAIN LOGISTICS, 2024-2032 (IN $
MILLION)
FIGURE 14: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY COLD CHAIN LOGISTICS, 2024-2032 (IN $
MILLION)
FIGURE 15: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY THERAPY AREA, 2023 & 2032 (IN %)
FIGURE 16: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY COMMUNICABLE DISEASES, 2024-2032 (IN $
MILLION)
FIGURE 17: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY ONCOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 18: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY DIABETES, 2024-2032 (IN $ MILLION)
FIGURE 19: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY CARDIOVASCULAR DISEASES, 2024-2032 (IN $
MILLION)
FIGURE 20: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY AUTOIMMUNE DISEASES, 2024-2032 (IN $
MILLION)
FIGURE 21: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY NEUROLOGICAL DISORDERS, 2024-2032 (IN $
MILLION)
FIGURE 22: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY PAIN MANAGEMENT, 2024-2032 (IN $ MILLION)
FIGURE 23: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY RESPIRATORY DISEASES, 2024-2032 (IN $
MILLION)
FIGURE 24: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY OTHER THERAPY AREAS, 2024-2032 (IN $
MILLION)
FIGURE 25: EUROPE
PHARMACEUTICAL LOGISTICS MARKET, BY COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 26: GERMANY
PHARMACEUTICAL LOGISTICS MARKET 2024-2032 (IN $ MILLION)
FIGURE 27: UNITED KINGDOM
PHARMACEUTICAL LOGISTICS MARKET 2024-2032 (IN $ MILLION)
FIGURE 28: FRANCE
PHARMACEUTICAL LOGISTICS MARKET 2024-2032 (IN $ MILLION)
FIGURE 29: ITALY
PHARMACEUTICAL LOGISTICS MARKET 2024-2032 (IN $ MILLION)
FIGURE 30: SPAIN
PHARMACEUTICAL LOGISTICS MARKET 2024-2032 (IN $ MILLION)
FIGURE 31: REST OF EUROPE
PHARMACEUTICAL LOGISTICS MARKET 2024-2032 (IN $ MILLION)